Luke Miels is GSKs Chief Commercial Officer and CEO Designate, set to take over leadership in early 2026. A seasoned pharmaceutical executive, his career includes senior roles at AstraZeneca, Roche, and Sanofi. He is recognized for driving commercial strategy and has been instrumental in building GSKs specialty medicines portfolio, particularly in oncology.
Originally from Australia, Luke began his career there after earning a Bachelor of Science from Flinders University and an MBA from Macquarie University. He has extensive international experience, having lived and worked in the US, Europe, and Asia while holding global leadership positions at top pharmaceutical companies.
He will become the CEO of GSK on January 1, 2026, succeeding Dame Emma Walmsley.